Drugs / TOSITUMOMAB 131I
TOSITUMOMAB 131I
also known as
Iodine I 131 Tositumomab · Iodine-131 Anti-B1 Antibody · Bexxar · I-131 TST · Iodine-131 Tositumomab · 131-I anti-B1 · 131I-Tositumomab · Coulter Clone 131Iodine-B1 · +2 more
Monoclonal antibody targets MS4A1
Trials 28
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT00434629 | Feb 2007 → May 2015 | B-cell non-Hodgkin lymphoma | University of Pennsylvania | Completed | No outcome recorded |
| Phase 1 | NCT00315731 | Mar 2003 → Dec 2006 | follicular lymphoma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00022880 | Jul 1999 → ? | chronic lymphocytic leukemia/small lymphocytic lymphoma | Corixa Corporation | Unknown | No outcome recorded |
| Phase 1 | NCT00992758 | May 1999 → Jun 2012 | non-Hodgkin lymphoma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00022906 | May 1999 → ? | non-Hodgkin lymphoma | Corixa Corporation | Unknown | No outcome recorded |
| Phase 1 | NCT01536561 | Apr 1990 → Jul 1997 | non-Hodgkin lymphoma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00062894 | Apr 2003 → Apr 2007 | non-Hodgkin lymphoma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 216 trials · 1 met primary | ||||||
| Phase 2 | NCT01389076 | Jul 2011 → Feb 2014 | follicular lymphoma | University of Michigan Rogel Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT00479167 | May 2007 → Sep 2008 | follicular lymphoma | Rush University Medical Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00476047 | Feb 2007 → Feb 2015 | chronic lymphocytic leukemia/small lymphocytic lymphoma | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00135200 | Aug 2005 → Aug 2013 | plasma cell myeloma | University of Michigan Rogel Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00490009 | Sep 2004 → Apr 2010 | lymphoma | Susan Knox | Completed | No outcome recorded |
| Phase 2 | NCT01868035 | May 2000 → Oct 2012 | non-Hodgkin lymphoma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT01663714 | Feb 2000 → Feb 2012 | non-Hodgkin lymphoma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00022932 | Jan 2000 → ? | non-Hodgkin lymphoma | Corixa Corporation | Unknown | No outcome recorded |
| Phase 2 | NCT00933335 | Aug 1998 → Dec 2009 | non-Hodgkin lymphoma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00996593 | Jul 1998 → Apr 2001 | non-Hodgkin lymphoma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00950755 | Jun 1998 → Apr 2011 | non-Hodgkin lymphoma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00938041 | Apr 1998 → May 2003 | non-Hodgkin lymphoma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00989664 | Nov 1996 → Jan 2004 | non-Hodgkin lymphoma | GlaxoSmithKline | Completed | Met primary |
| Phase 2 | NCT00996996 | Jun 1996 → Mar 1999 | B-cell non-Hodgkin lymphoma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT01224821 | Dec 1995 → Nov 1997 | non-Hodgkin lymphoma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00022945 | — | mantle cell lymphoma | Corixa Corporation | Completed | No outcome recorded |
| Phase 33 trials · 1 missed | ||||||
| Phase 3 | NCT00329030 | Dec 2005 → Aug 2013 | B-cell non-Hodgkin lymphoma, large-cell immunoblastic lymphoma | National Heart, Lung, and Blood Institute (NHLBI) | Completed | Missed primary |
| Phase 3 | NCT00319332 | Sep 2005 → Feb 2021 | follicular lymphoma | GlaxoSmithKline | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00268983 | Oct 2004 → Sep 2009 | B-cell non-Hodgkin lymphoma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT00022958 | Sep 1998 → ? | non-Hodgkin lymphoma | Corixa Corporation | Unknown | No outcome recorded |
| — | NCT00022893 | — | non-Hodgkin lymphoma | Corixa Corporation | Unknown | No outcome recorded |
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 29 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TOSITUMOMAB 131I | ChEMBL registry synonym — accepted as the source's own label CHEMBL3833304 ↗ |
| Known as | 131-I anti-B1 | “131-I anti-B1 is the product of 131-I labeling of the anti-CD20 murine monoclonal antibody and the anti-B1 antibody itself is an intact IgG2a murine monoclonal antibody which...” NCT01536561 ↗ |
| Known as | 131I-Tositumomab | “test dose of 131I-Tositumomab, IV (in the vein) to determine treatment dose of 131I-Tositumomab” NCT00434629 ↗ |
| Known as | Bexxar | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00329030 ↗ |
| Known as | Coulter Clone 131Iodine-B1 | “Study of Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas and Extended Study to Determine the Safety and Efficacy of Coulter Clone® 131Iodine-B1...” NCT01536561 ↗ |
| Known as | I-131 TST | “Tositumomab and Iodine I 131 Tositumomab (TST/I-131 TST)” NCT00989664 ↗1“tositumomab (TST) and iodine-131 tositumomab (I-131 TST)” PMID 32800518 ↗ Apr 2019 |
| Known as | Iodine I 131 Tositumomab | “Patients will receive an infusion of unlabeled Tositumomab (450 mg) immediately followed by an infusion of the patient specific dose of tellurium-derived Iodine I 131...” NCT00315731 ↗ |
| Known as | Iodine-131 Anti-B1 Antibody | “Tositumomab and Iodine I 131 Tositumomab (Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody)” NCT00996996 ↗ |
| Known as | Iodine-131 Tositumomab | “Phase 2 Study of Iodine-131 Tositumomab Plus Chemotherapy in Patients With Previously Untreated Mantle-Cell Lymphoma.” PMID 32800518 ↗ Apr 2019 |
| Known as | Tositumomab I-131 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00479167 ↗ |
| Known as | Tositumomab/iodine (131i) tositumomab | ChEMBL registry synonym — accepted as the source's own label CHEMBL3833304 ↗ |
| Action | Deplete | “The radioactive isotope then gives off radiation, which kills the cells.” NCT00490009 ↗ |
| Modality | Other / unclassified | “Bexxar (Tositumomab and Iodine I 131 Tositumomab) is a radioimmunoconjugate with demonstrated anti-lymphoma effects.” NCT00329030 ↗ |
| Route | Other | “an infusion of the patient specific dose of tellurium-derived Iodine I 131 Tositumomab (35 mg)” NCT00315731 ↗ |
| Target | MS4A1 | “B-lymphocyte antigen CD20 binding agent” CHEMBL3833304 ↗ |